Baseline characteristics and scores on clinical scales and cognitive testing at baseline and at 12-month follow-up and change in scores between time points for Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) groups
| AD (n=100) | DLB (n=58) | p | |
| Gender (M:F) | |||
| M | 48 (48%) | 37 (64%) | 0.06 |
| F | 52 (52%) | 21 (36%) | |
| Age in years at 123I-FP-CIT SPECT session | 74.9 (7.3) | 74.2 (6.1) | 0.53 |
| Cornell Scale for Depression in Dementia (baseline) | 3.8 (3.3) | 6.6 (3.4) | <0.001 |
| Cholinesterase inhibitor | 82 (82%) | 45 (76%) | 0.50 |
| Memantine | 9 (9%) | 2 (3%) | 0.19 |
| Neuroleptic medication | 4 (4%) | 9 (16%) | 0.01 |
| Clinical Dementia Rating (baseline) | 1.2 (0.69) | 1.3 (0.66) | 0.3 |
| MMSE score (SD) | |||
| Baseline | 21.5 (4.5) | 21.4 (3.9) | 0.85 |
| Follow-up | 19.0 (6.2) | 18.5 (6.0) | 0.65 |
| Change | 2.6 (4.0) | 3.1 (4.3) | 0.40 |
| CAMCOG score (SD) | |||
| Baseline | 66.3 (15.6) | 66.0 (13.5) | 0.89 |
| Follow-up | 59.5 (20.3) | 56.3 (19.7) | 0.35 |
| Change | 7.5 (10.6) | 9.0 (11.9) | 0.429 |
| NPI score (SD) | |||
| Baseline | 9.7 (10.3) | 19.8 (14.6) | <0.001 |
| Follow-up | 12.3 (13.3) | 24.2 (17.4) | <0.001 |
| Change | 2.5 (14.8) | 3.8 (15.5) | 0.59 |
| NPI-carer score (SD) | |||
| Baseline | 5.8 (6.0) | 10.8 (8.0) | <0.001 |
| Follow-up | 5.8 (5.7) | 11.8 (8.6) | <0.001 |
| Change | −0.05 (6.4) | 0.8 (7.1) | 0.44 |
| Fluctuations | |||
| Baseline | 0.6 (2.1) | 6.0 (4.5) | <0.001 |
| Follow-up | 0.4 (1.7) | 6.9 (4.1) | <0.001 |
| Change | −0.2 (2.4) | 0.8 (4.1) | 0.07 |
| CAMCOG executive function | |||
| Baseline | 11.9 (5.2) | 11.1 (4.7) | 0.33 |
| Follow-up | 10.5 (5.4) | 9.4 (5.0) | 0.24 |
| Change | 1.5 (3.6) | 1.4 (4.0) | 0.83 |
Data are presented as mean (SD) or number (%). p=p Values (analysis of variance).
CAMCOG, Cambridge Cognitive Examination; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.